Cargando…
DIPG-33. P16 IMMUNOHISTOCHEMICAL EXPRESSION AS A SURROGATE ASSESSMENT OF CDKN2A ALTERATION IN GLIOMAS LEADING TO PROGNOSTIC SIGNIFICANCES
CDKN2A is a tumor suppressor gene encoding for p16 protein. Its homozygous deletion is a central prognostic factor for numerous brain cancers. This deletion can be detected by several techniques. Up to now, immunohistochemistry (IHC) using p16 antibody is not recommended as a surrogate test. This st...
Autores principales: | Geyer, Lucas, Wolf, Thibaut, Chenard, Marie Pierre, Cebula, Helene, Schott, Roland, Noel, Georges, Guerin, Eric, Pencreach, Erwan, Reita, Damien, ENTZ-WERLE, Natacha, Lhermitte, Benoit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260083/ http://dx.doi.org/10.1093/neuonc/noad073.080 |
Ejemplares similares
-
DIPG-31. HIF-1A AND HIF-2A COMBINATORIAL TARGETING OR HOW TO REVERSE THEIR BALANCED ONCOGENIC IMPACT
por: Fuchs, Quentin, et al.
Publicado: (2023) -
DIPG-30. HIF2 OVEREXPRESSION DICTATES AGGRESSIVENESS ADDITIONALLY TO TP53 MUTATIONS IN H3.3K27M PEDIATRIC HIGH-GRADE GLIOMAS THROUGH RAS-MAPK AND WNT/BCATENIN PATHWAYS
por: Fuchs, Quentin, et al.
Publicado: (2023) -
DIPG-48. DIPG THROUGH THE LOOKING GLASS
por: Senga, Sasi S
Publicado: (2023) -
DIPG-05. EVALUATION OF TELOMERE-MODIFYING COMPOUND THIO AS A RADIOSENSITIZER AND IMMUNOMODULATOR TO TREAT DIPG
por: Mishra, Deepak, et al.
Publicado: (2023) -
DIPG-27. DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) CHALLENGE: FROM GENE EXPRESSION PROFILE TO DRUG
por: Scilimati, Antonio, et al.
Publicado: (2023)